LoadingLoadingLoading48 funds hold it.Insiders net selling.
Net selling: insiders sold $39.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 21, 2026
Financial period
Third Quarter 2026
Earnings per share
$6.40 expected
Revenue
$11.95B expected
Estimates as of Nov 3, 2026
EPS expected
$7.00 to $7.34
Revenue expected
20 analysts
Last 30 days
Split both ways
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 26, 2026Reported Oct 21, 2026 | $6.68est. $6.40 | +4.33%beat | $12.14Best. $11.95B+1.59% | +9.2%from $11.12B |
| Jun 27, 2026Reported Jul 23, 2026 | $6.03est. $5.71 | +5.55%beat | $11.99BCompany release | +10.5%from $10.86B |
| Mar 28, 2026Reported Apr 23, 2026 | $5.44est. $5.24 | +3.79%beat | $11.01BSEC filing | +6.2%from $10.36B |
| Dec 31, 2025Reported Jan 29, 2026 | $6.57est. $6.45 | +1.87%beat | $12.21BAlpha Vantage | +7.2%from $11.39B |
| Sep 27, 2025Reported Oct 22, 2025 | $5.79est. $5.50 | +5.27%beat | $11.12BSEC filing | +4.9%from $10.60B |
| Jun 28, 2025Reported Jul 23, 2025 | $5.36est. $5.23 | +2.49%beat | $10.86BSEC filing | +3.0%from $10.54B |
| Mar 29, 2025Reported Apr 23, 2025 | $5.15est. $5.10 | +0.98%in line | $10.36BSEC filing | +0.2%from $10.35B |
| Dec 31, 2024Reported Jan 30, 2025 | $6.10est. $5.94 | +2.69%beat | $11.39BAlpha Vantage | +4.7%from $10.89B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $12.21B | $11.01B | $11.99B | $12.14B |
| Cost of what it sold | $7.20B | $6.53B | $7.05B | $6.95B |
| Gross profit | $5.01B | $4.48B | $4.94B | $5.19B |
| What it spent | ||||
| Research and development | $357.0M | $336.0M | $364.0M | $348.0M |
| Sales and admin | $1.98B | $2.18B | $1.91B | $1.86B |
| Other operating costs | $374.0M | $96.0M | $583.0M | $718.0M |
| Total operating expenses | $2.71B | $2.61B | $2.86B | $2.93B |
| What was left | ||||
| Operating profit | $2.30B | $1.86B | $2.09B | $2.26B |
| Interest on debt | $365.0M | $354.0M | $401.0M | $417.0M |
| Profit before tax | $2.12B | $1.73B | $1.92B | $2.09B |
| Tax | $153.0M | $70.0M | $167.0M | $352.0M |
| Net profit | $1.98B | $1.65B | $1.74B | $1.72B |
| EBITDA | $3.22B | $2.62B | $2.90B | $2.50B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Thermo Fisher Scientific Authorizes $5 Billion Share Buyback after Upbeat Earnings
BullishNov 6Charles River Laboratories International, Inc. Just Beat EPS By 244%: Here's What Analysts Think Will Happen Next
NeutralNov 6Thermo Fisher Scientific announces $5B share repurchase authorization
BullishNov 6Thermo Fisher Scientific launches AmpSure master mixes for everyday qPCR
BullishNov 6Arcturus Therapeutics Q3 Results: Net loss narrows to $7.4 million
Leans bullishNov 6Arcturus Therapeutics Q3 2026 Earnings Call Transcript
Leans bullishNov 5Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
BullishNov 5Thermo Fisher declares $0.47 quarterly dividend
Leans bullishNov 531 macro signals shaping TMO right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
